Adalimumab |
Adalimumab Products |
| Pocket Pharma: Adalimumab P. Emery Science Press Science Press |
Sale Price: $15.95
|
| Adalimumab + methotrexate slows RA progression; about 60% achieve ACR 20. (rheumatoid arthritis).(Clinical Rounds): An article from: Internal Medicine News Diana Mahoney International Medical News Group International Medical News Group |
Sale Price: $5.95
|
| Adalimumab looks good for psoriasis.(Skin Disorders): An article from: Family Practice News Michele G. Sullivan International Medical News Group International Medical News Group |
Sale Price: $5.95
|
| Adalimumab maintains Crohn's disease remission; the subcutaneously injected drug is currently approved by the FDA for the treatment of arthritis.(Digestive ... An article from: Family Practice News Mitchel L. Zoler Thomson Gale Thomson Gale |
Sale Price: $5.95
|
| Adalimumab offered free for certain seniors. (Costly Rheumatoid Arthritis Drug).(antirheumatic agent): An article from: Family Practice News Nancy Walsh International Medical News Group International Medical News Group |
Sale Price: $5.95
|
| Adalimumab holds Crohn's disease in check: a larger study is underway to definitively assess the drug's long-term efficacy for preventing recurrence.(Gastroenterology)(Drug ... An article from: Internal Medicine News Mitchel L. Zoler Thomson Gale Thomson Gale |
Sale Price: $5.95
|
| Adalimumab offered at no cost to seniors who lack drug coverage. (Until Medicare Drug Benefit Enacted).: An article from: Internal Medicine News Nancy Walsh International Medical News Group International Medical News Group |
Sale Price: $5.95
|
| Adalimumab advised for recalcitrant psoriasis.(Dermatologic Therapy): An article from: Skin & Allergy News Michele G. Sullivan International Medical News Group International Medical News Group |
Sale Price: $5.95
|
| Psoriasis, psoriatic arthritis improved with adalimumab.: An article from: Internal Medicine News Michele G. Sullivan Thomson Gale Thomson Gale |
Sale Price: $5.95
|
| Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-Cell-targeted therapies ... from: Journal of Drugs in Dermatology Jeffrey M. Weinberg, Clement J. Bottino, James Lindholm, Robin Buchholz Thomson Gale Thomson Gale |
Sale Price: $5.95
|

Not Signed In - 

